EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has embarked on a pre-clinical study to test its exosome-based therapy ExoPTEN for regenerating damaged optic nerves, a breakthrough that could potentially restore vision in cases of glaucoma and other conditions leading to blindness. The market for optic nerve disorder treatments, currently valued at US$3.4 billion, may witness a paradigm shift if NurExone’s innovative treatment, already showing promise in spinal cord injuries, proves to be successful in upcoming trials. This research could redefine the approach to treating optic nerve damage and offer new hope to millions affected by vision loss.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
